Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and
docetaxel, to find out which treatment is better for people with sarcomas.
Phase:
Phase 3
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Connective Tissue Oncology Society M.D. Anderson Cancer Center Massachusetts General Hospital Mayo Clinic University of Michigan Cancer Center University of Michigan Rogel Cancer Center